Treatment resistant schizophrenia (TRS) has a severe clinical and economic impact on patients, carers, families and society as the whole. Research on TRS has generated several hypotheses to explain the underlying pathophysiology. This video provides an overview of one such hypothesis.
Related content
In this video Professor Christoph Correll discusses the challenges with available schizophrenia treatments & what clinicians should keep in mind when considering the emerging treatment options for schizophrenia.
The table summarizes the high-level clinical characteristics of the existing and newly emerging pharmacological treatments for schizophrenia with at least one positive placebo-controlled trial.
LDT=Laterodorsal tegmental nucleus; NAc = Nucleus Accumbens; SN = Substantia Nigra; VTA = Ventral Tegmental Area.